Industry

Invisalign® Palatal Expanders offer doctors an effective and easily removeable alternative to traditional palatal expanders, without the need for metal and screws. Combined with Invisalign First™ aligners, Invisalign Palatal Expanders provide doctors with a full early intervention treatment solution, including both skeletal (orthopedic) and dental (orthodontic) arch expansion. MUMBAI, India–(BUSINESS WIRE)–Align Technology, Inc. (“Align”) (Nasdaq: … [Read more…]

– All eligible people with CF in England can now benefit from this medicine – LONDON–(BUSINESS WIRE)–Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced today that it has reached a broad reimbursement agreement with NHS England for Vertex’s cystic fibrosis (CF) medicine ALYFTREK® (deutivacaftor/tezacaftor/vanzacaftor). This agreement comes as the National Institute for Health and Care Excellence (NICE) … [Read more…]

ROME, Ga.–(BUSINESS WIRE)–AdventHealth and Anthem Blue Cross Blue Shield of Georgia (Anthem) are pleased to announce a new multi-year contractual agreement that ensures continued access to high-quality, compassionate care for Anthem members across Northwest Georgia. This agreement solidifies the long-standing partnership between two of the region’s most trusted health care organizations. It guarantees that Anthem … [Read more…]

OTTAWA, Ontario–(BUSINESS WIRE)–The members of CUPE local 5102 were proud to invite the wider community to join them in celebrating the hard work their members provide to the residents of Red Oak retirement community in Kanata. The ice cream social at 3501 Campeau Dr. ran from 1PM to 5PM on July 11. Local City Councillor … [Read more…]

Partnership improves access to great dermatologic care AUSTIN, Texas–(BUSINESS WIRE)–Epiphany Dermatology, a leading dermatology company committed to improving access to exceptional dermatologic care, announced today it has expanded its presence in the St. Louis market through its partnership with Associates in Dermatology & Cutaneous Surgery, Ltd. (AIDCS). Upon joining AIDCS in 1991 and then becoming … [Read more…]

CHICAGO–(BUSINESS WIRE)–ComPsych® Corporation, the worldwide leader in organizational mental health, well-being, and absence management, today celebrated the relocation of its global corporate headquarters to One Prudential Plaza located at 130 E. Randolph Street in Chicago. The 50,000-square foot space provides ample room for both Chicago-based and visiting employees to work and collaborate, including a state-of-the-art … [Read more…]

Partnership will accelerate and broaden access to treatment for more patients with generalized pustular psoriasis (GPP), a rare and devastating skin condition LEO Pharma’s six decades of dermatology expertise and Boehringer’s global track record in bringing SPEVIGO® to over 40 countries will be combined to ensure continuous patient support Boehringer Ingelheim and LEO Pharma will … [Read more…]

– Both Phase 3 Studies Met all Primary and Secondary Endpoints Demonstrating Statistically Significant Improvements Across Symptoms at All Doses, Building Upon Phase 2b Results – Oveporexton was Generally Well-Tolerated in Phase 3 Safety Profile – Takeda is Rapidly Advancing Regulatory Submissions and Launch Preparedness with the Aim to Bring Oveporexton to People Living with … [Read more…]

SHANGHAI–(BUSINESS WIRE)–Golden Age Health Pte. Ltd. (“GAH”) and Innostellar Biotherapeutics Co., Ltd. (“Innostellar”) today announced an exclusive ten-year Promotion Services Agreement that grants GAH sole rights to commercialise and promote Innostellar’s first-in-class gene-therapy candidate LX-101 across Mainland China. Leveraging its full-spectrum patient-focused launch platform covering disease and medical education, market access and patient support to … [Read more…]

– Pivotal Phase 3 LUCIDITY trial of avexitide, a potential first-in-class GLP-1 receptor antagonist with FDA Breakthrough Therapy designation, underway in post-bariatric hypoglycemia; completion of recruitment expected in 2025, with topline data anticipated in first half of 2026 – In the Phase 2b trial, avexitide 90 mg once daily led to a 64% least-squares mean … [Read more…]